Description

SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB[1].–80°C, stored under nitrogen-Applications-Cancer-programmed cell death-Formula-C63H97N11O16-Citation–References-[1]Kamath AV, et al. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. Pharm Res. 2015 Nov;32(11):3470-9.-CASNumber–MolecularWeight-1264.51-Compound Purity-99.24-SMILES-CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(ON4C(CCC4=O)=O)=O)=O)=O)C=C3)=O)C)=O)=O)C-Research_Area-Cancer-Solubility-DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C)-Target-Drug-Linker Conjugates for ADC-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related